File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis

TitleDeleterious effect of prednisolone in HBsAg-positive chronic active hepatitis
Authors
Issue Date1981
PublisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/
Citation
New England Journal Of Medicine, 1981, v. 304 n. 7, p. 380-386 How to Cite?
AbstractTo study the efficacy of corticosteroids in chronic active hepatitis (CAH) positive for hepatitis B surface antigen (HBsAg), we pair-randomized 51 patients to receive either 15 to 20 mg of prednisolone per day or a placebo. After initial remission, the maintenance dosage of prednisolone was 10 mg per day, and the patients were prospectively followed for up to 3.5 years. Prednisolone decreased serum bilirubin (P<0.05) and globulin (P<0.01) at three months; it delayed other biochemical remission occurring after the second month of medication (P<0.001); it hastened biochemical relapse (P<0.0001); and it increased the frequency of complications (P<0.0001) and the death rate (P<0.01). We conclude that prednisolone has an overall harmful effect in patients with HBsAg-positive CAH.
Persistent Identifierhttp://hdl.handle.net/10722/161655
ISSN
2015 Impact Factor: 59.558
2015 SCImago Journal Rankings: 14.619
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLam, KCen_US
dc.contributor.authorLai, CLen_US
dc.contributor.authorNg, RPen_US
dc.date.accessioned2012-09-05T05:13:35Z-
dc.date.available2012-09-05T05:13:35Z-
dc.date.issued1981en_US
dc.identifier.citationNew England Journal Of Medicine, 1981, v. 304 n. 7, p. 380-386en_US
dc.identifier.issn0028-4793en_US
dc.identifier.urihttp://hdl.handle.net/10722/161655-
dc.description.abstractTo study the efficacy of corticosteroids in chronic active hepatitis (CAH) positive for hepatitis B surface antigen (HBsAg), we pair-randomized 51 patients to receive either 15 to 20 mg of prednisolone per day or a placebo. After initial remission, the maintenance dosage of prednisolone was 10 mg per day, and the patients were prospectively followed for up to 3.5 years. Prednisolone decreased serum bilirubin (P<0.05) and globulin (P<0.01) at three months; it delayed other biochemical remission occurring after the second month of medication (P<0.001); it hastened biochemical relapse (P<0.0001); and it increased the frequency of complications (P<0.0001) and the death rate (P<0.01). We conclude that prednisolone has an overall harmful effect in patients with HBsAg-positive CAH.en_US
dc.languageengen_US
dc.publisherMassachusetts Medical Society. The Journal's web site is located at http://content.nejm.org/en_US
dc.relation.ispartofNew England Journal of Medicineen_US
dc.subject.meshAdulten_US
dc.subject.meshAlanine Transaminase - Blooden_US
dc.subject.meshAspartate Aminotransferases - Blooden_US
dc.subject.meshBilirubin - Blooden_US
dc.subject.meshChronic Diseaseen_US
dc.subject.meshClinical Trials As Topicen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis - Drug Therapyen_US
dc.subject.meshHepatitis B - Drug Therapyen_US
dc.subject.meshHepatitis B Surface Antigens - Analysisen_US
dc.subject.meshHumansen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshPrednisolone - Adverse Effects - Therapeutic Useen_US
dc.subject.meshProspective Studiesen_US
dc.subject.meshRandom Allocationen_US
dc.subject.meshRemission, Spontaneousen_US
dc.subject.meshSerum Globulins - Analysisen_US
dc.titleDeleterious effect of prednisolone in HBsAg-positive chronic active hepatitisen_US
dc.typeArticleen_US
dc.identifier.emailLai, CL:hrmelcl@hku.hken_US
dc.identifier.authorityLai, CL=rp00314en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1056/NEJM198102123040702-
dc.identifier.pmid7005678en_US
dc.identifier.scopuseid_2-s2.0-0019363534en_US
dc.identifier.volume304en_US
dc.identifier.issue7en_US
dc.identifier.spage380en_US
dc.identifier.epage386en_US
dc.identifier.isiWOS:A1981LA46600002-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridLam, KC=7403657286en_US
dc.identifier.scopusauthoridLai, CL=7403086396en_US
dc.identifier.scopusauthoridNg, RP=7102153823en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats